Idenix Pharmarceuticals (IDIX) adds $2.80 to $9.85 on positive trial results from a Hepititis C drug and one player seized the strength to write 10,000 Jan $10 calls on the biotech for an average of 52.5 cents per contract to open. 12,618 now traded against 278 in open interest. Meanwhile, implied volatility in options on IDIX is up another 20 percent to 137, even as this company event-risk has passed. Briefing notes today that IDIX and peer ACHN have both been considered M&A candidates and another name in the space — INHX — was taken out at a hefty premium by BMY over the weekend.